Concepedia

Asari Ekpenyong

AE

4

Publications

127

Citations

4

H-Index

2022

Active since

Affiliations

Emory University(Current)

Astellas Pharma (United States)

Moffitt Cancer Center

Asari Ekpenyong is an author at Emory University specializing in cancer therapeutics, oncology, and pathology.

Top concepts

MedicineOncologyPathologyCancer TherapyRadiation OncologyHead And Neck CancerHealthImmunologyImmunotherapyTumor Immunity

Publications per year

2022–2024

4

Publications

4

Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial

Nabil F. Saba, Conor Steuer, Asari Ekpenyong et al. · Nature Medicine · 2023 · 73 citations · Full text

Oncology, Pathology, Immune Checkpoint Inhibitor +7

HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer

Fanghui Chen, Chris Tang, Fan Yang et al. · Science Advances · 2024 · 30 citations · Full text

A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC).

Nabil F. Saba, Asari Ekpenyong, Ashley McCook-Veal et al. · Journal of Clinical Oncology · 2022 · 12 citations

Rm Hnscc, Immunology, Pathology +19

Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma

Nabil F. Saba, Stuart J. Wong, Tahseen H. Nasti et al. · JAMA Oncology · 2024 · 12 citations · Full text

Rows per page

1–4 of 4